J&J Faulty Hip Implants: Health Ministry Approves Compensation Formula
The Health Ministry approved the formula for determination of compensation for patients who prior to August 2010, had received faulty articular surface replacement hip implants manufactured by Johnson & Johnson.
The government had constituted a central expert committee under the chairmanship of Dr. R K Arya, director, Sports Injury Centre, to determine the quantum of compensation.
The central expert committee, after holding five meetings, prepared a formula for determining compensation for the ASR victim patients, which has been approved by the ministry.
"Compensation will be paid in a time bound manner through bank accounts of affected persons by M/S Johnson & Johnson Pvt. Ltd.," a statement from the ministry stated.
Sh @JPNadda: happy that @MoHFW_INDIA today approved formula for compensation to patients who received faulty ASR hip implants manufactured by M/s Johnson & Johnson Pvt Ltd. I am committed to ensuring that patients get their due compensation without any hardship. pic.twitter.com/DdTvNA2s3x
November 29, 2018The compensation payable to patients will be determined in terms of the disability caused by the faulty hip implants in relation to their age, it said.
According to the statement, those between 20 to 35 years would get compensation between:
- Rs 58.08 lakh and Rs 49.66 lakh for 20 to 30 percent disability
- Rs 77.63 lakh to Rs 69.41 lakh for 30 to 40 precent disability
- Rs 100.17 lakh to 89.32 lakh for 40 to 50 percent disability and
- Rs 122.71 lakh to Rs 109.15 lakh over 60 precent disability
Those between 35 to 60 will get a compensation between:
- Rs 49.66 lakh and Rs 33.63 lakh for 30 percent disability
- Rs 69.49 lakh to Rs 44.45 lakh for 30 to 40 precent disability
- Rs 89.32 lakh to Rs 57.26 lakh for 40 to 50 percent disability and
- Rs 109.15 lakh to 69.08 lakh for over 60 precent disability
Those above 65 will get:
- Rs 30 lakh for 20 to 30 percent disability
- Rs 40 for 30 to 40 percent disability
- Rs 50 lakh for 40 to 50 percent disability and
- Rs 60 lakh for over 60 percent disability
Earlier, the ministry had asked states and union territories to form committees to examine cases of affected patients and to make the process less arduous for them.
These committees were directed to send their recommendations to the central expert committee.
The states and union territories had also been asked to make people aware through newspaper advertisements so that they could approach either the central committee or state-level committees.
In a report earlier, an expert panel had suggested that the firm pay compensation of around Rs 20 lakh to the affected patients.
The report was made public after patients demanded that it be put in the public domain.
The committee, in its report, stated that "the ASR hip implants manufactured by DePuy International Ltd were found to be faulty which resulted in higher instances of revision surgeries globally including India".
The report recommended DePuy International Ltd., a subsidiary of Johnson and Johnson, be made liable to pay at least Rs 20 lakh to each affected patient, and the reimbursement for revision surgeries should continue until August 2025.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
